KR20220006551A - 관절염 질환의 병용 치료 - Google Patents

관절염 질환의 병용 치료 Download PDF

Info

Publication number
KR20220006551A
KR20220006551A KR1020217038762A KR20217038762A KR20220006551A KR 20220006551 A KR20220006551 A KR 20220006551A KR 1020217038762 A KR1020217038762 A KR 1020217038762A KR 20217038762 A KR20217038762 A KR 20217038762A KR 20220006551 A KR20220006551 A KR 20220006551A
Authority
KR
South Korea
Prior art keywords
optionally substituted
composition
formula
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217038762A
Other languages
English (en)
Korean (ko)
Inventor
토마스 엥겔브레츠 노드킬드 조나센
Original Assignee
신액트 파마 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신액트 파마 에이피에스 filed Critical 신액트 파마 에이피에스
Publication of KR20220006551A publication Critical patent/KR20220006551A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217038762A 2019-05-10 2020-05-07 관절염 질환의 병용 치료 Pending KR20220006551A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19173734 2019-05-10
EP19173734.5 2019-05-10
PCT/EP2020/062711 WO2020229297A1 (en) 2019-05-10 2020-05-07 Combination treatment of arthritic disease

Publications (1)

Publication Number Publication Date
KR20220006551A true KR20220006551A (ko) 2022-01-17

Family

ID=66483881

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217038762A Pending KR20220006551A (ko) 2019-05-10 2020-05-07 관절염 질환의 병용 치료

Country Status (21)

Country Link
US (2) US12303489B2 (https=)
EP (2) EP3773558B1 (https=)
JP (1) JP7546599B2 (https=)
KR (1) KR20220006551A (https=)
CN (1) CN113795250B (https=)
AU (1) AU2020273479B2 (https=)
BR (1) BR112021022397A2 (https=)
CA (1) CA3139000A1 (https=)
CY (1) CY1125564T1 (https=)
DK (1) DK3773558T3 (https=)
ES (2) ES2927294T3 (https=)
HU (1) HUE059638T2 (https=)
IL (1) IL287904B2 (https=)
LT (1) LT3773558T (https=)
MX (1) MX2021013296A (https=)
PL (1) PL3773558T3 (https=)
PT (1) PT3773558T (https=)
SG (1) SG11202111821SA (https=)
SI (1) SI3773558T1 (https=)
WO (1) WO2020229297A1 (https=)
ZA (1) ZA202108219B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3773558T (lt) 2019-05-10 2022-09-12 Synact Pharma Aps Kompleksinis artrito gydymas
CN120617247A (zh) * 2020-03-31 2025-09-12 西奈克制药有限公司 症状性病毒性疾病的治疗
WO2022223778A1 (en) 2021-04-23 2022-10-27 Helmholtz-Zentrum für Infektionsforschung GmbH Citraconic acid and derivatives thereof for use as a medicament
EP4359076B1 (en) 2021-06-21 2025-08-06 SynAct Pharma ApS Phenyl pyrrole aminoguanidine salts and formulations
US20250032449A1 (en) * 2021-11-29 2025-01-30 Synact Pharma Aps Treatment of rheumatoid arthritis
WO2023218048A1 (en) * 2022-05-12 2023-11-16 Synact Pharma Aps Resomelagon and its derivatives for the treatment of cardiovascular disease, hypertension and atherosclerosis
CN120584099A (zh) * 2022-12-21 2025-09-02 西奈克制药有限公司 苯基吡咯肼甲脒化合物的多晶型物
WO2025124760A1 (en) 2023-12-11 2025-06-19 Synact Pharma Aps Treatment of subpopulation of patients with rheumatoid arthritis

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604348D0 (sv) 1996-11-26 1996-11-26 Wapharm Ab Användning av hydroxyguanidiner
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2001005401A1 (en) 1999-07-16 2001-01-25 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
WO2001055107A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
WO2001055106A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Novel melanocortin receptor agonists and antagonists
GB0002059D0 (en) 2000-01-28 2000-03-22 Melacure Therapeutics Ab Novel aromatic amines
KR100440370B1 (ko) 2000-04-01 2004-07-19 (주)명문엘씨 2중 사출에 의한 밀폐용기 뚜껑
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
EP1370211A4 (en) 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
GB0119172D0 (en) 2001-08-06 2001-09-26 Melacure Therapeutics Ab Phenyl pyrrole derivatives
CA2363528A1 (en) 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
GB2398299A (en) 2003-02-13 2004-08-18 Melacure Therapeutics Ab Pharmaceutically active phenyl-pyrrole derivatives
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
NZ573457A (en) * 2006-06-09 2011-06-30 Action Pharma As Phenyl pyrrole aminoguanidine derivatives
GB0624987D0 (en) 2006-12-14 2007-01-24 Acure Pharma Ab Novel aminoguanidines as melanocortin receptor ligands
EP2045250A1 (en) 2007-09-26 2009-04-08 Action Pharma A/S Ring-substituted phenyl pyrrole aminoguanidine derivatives
WO2009071101A1 (en) 2007-12-07 2009-06-11 Action Pharma A/S N-modified aminoguanidine derivatives
WO2009074157A1 (en) 2007-12-13 2009-06-18 Action Pharma A/S Fully-modified phenyl pyrrole aminoguanidines
US10387927B2 (en) 2010-01-15 2019-08-20 Dell Products L.P. System and method for entitling digital assets
JP2011190199A (ja) * 2010-03-12 2011-09-29 Hideto Nakamura 関節リウマチ薬
US9662807B2 (en) 2011-12-21 2017-05-30 GKN Aerospace Services Structures, Corp. Method for forming a fabric preform for a composite material by separately tensioning tows
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
US9917808B2 (en) 2013-03-14 2018-03-13 International Business Machines Corporation Grouping electronic messages
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
CN112292125B (zh) 2018-06-22 2023-10-31 西奈克制药有限公司 蛋白尿的治疗
WO2020107221A1 (en) 2018-11-27 2020-06-04 Tsinghua University Chemical activators of nicotinamide mononucleotide adenlyly transferase 2 (nmnat2) and uses thereof
LT3773558T (lt) 2019-05-10 2022-09-12 Synact Pharma Aps Kompleksinis artrito gydymas
CN113730797B (zh) 2020-05-29 2023-05-16 创领心律管理医疗器械（上海）有限公司 电极板及可穿戴式除颤设备

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026049571A1 (ko) * 2024-08-29 2026-03-05 루다큐어 주식회사 통증 치료용 조성물

Also Published As

Publication number Publication date
US20220211666A1 (en) 2022-07-07
LT3773558T (lt) 2022-09-12
IL287904A (en) 2022-01-01
US12303489B2 (en) 2025-05-20
CN113795250B (zh) 2024-10-15
JP2022531906A (ja) 2022-07-12
ES3041907T3 (en) 2025-11-17
PT3773558T (pt) 2022-09-13
CY1125564T1 (el) 2026-02-25
EP3773558A1 (en) 2021-02-17
EP4119140A1 (en) 2023-01-18
US20250387365A1 (en) 2025-12-25
ES2927294T3 (es) 2022-11-04
IL287904B2 (en) 2026-03-01
SI3773558T1 (sl) 2022-11-30
AU2020273479A1 (en) 2021-12-23
DK3773558T3 (da) 2022-09-19
EP4119140C0 (en) 2025-06-25
EP4119140B1 (en) 2025-06-25
IL287904B1 (en) 2025-11-01
WO2020229297A1 (en) 2020-11-19
PL3773558T3 (pl) 2022-10-03
JP7546599B2 (ja) 2024-09-06
HUE059638T2 (hu) 2022-12-28
CA3139000A1 (en) 2020-11-19
SG11202111821SA (en) 2021-11-29
ZA202108219B (en) 2023-03-29
EP3773558B1 (en) 2022-06-15
AU2020273479B2 (en) 2025-02-27
MX2021013296A (es) 2021-12-15
CN113795250A (zh) 2021-12-14
BR112021022397A2 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
KR20220006551A (ko) 관절염 질환의 병용 치료
JP5819328B2 (ja) ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
US8784812B2 (en) Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
CN105228453B (zh) 用于治疗与炎症相关的疾病的去乙基羟氯喹
AU2016396658B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
US20110136835A1 (en) Combination formulations of tranilast and allopurinol and methods related thereto
RU2322238C2 (ru) Лечение ревматоидного артрита
JP2017525719A (ja) 関節リウマチの治療における１つの丸剤・錠剤・カプセル剤でのミノサイクリン、アシクログアノシン、アトルバスタチンおよびビタミンｄの使用
RU2828044C2 (ru) Комбинированное лечение артрита
WO2023094692A1 (en) Treatment of rheumatoid arthritis
HK40047132B (en) Combination treatment of arthritic disease
HK40047132A (en) Combination treatment of arthritic disease
WO2025124760A1 (en) Treatment of subpopulation of patients with rheumatoid arthritis
Kong et al. Clinicopathological conference: amyloidosis and light chain myeloma in a 68-year-old man
ISMAIL RESPIRATORY INVOLVEMENT IN RHEUMATOID ARTHRITIS PHYSIOLOGIC ABNORMALITIES AND DETERMINANTS OF RADIOGRAPIDC
HK1128426A (en) Methods for treating autoimmune diseases using a taci-ig fusion molecule

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000